Eli Lilly and Co (XSWX:LLY) Inventories, Other: CHF29 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:LLY Eli Lilly and Co XSWX:LLY
99 GF Score
Price CHF955.00
GF Value CHF1,136.02
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Inventories, Other?

Eli Lilly and Co XSWX:LLY 99 Inventories, Other is CHF29 Mil as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 99/100 and a GF Value™ of CHF1,136.02 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Eli Lilly and Co's other inventories for the quarter that ended in Mar. 2026 was CHF29 Mil.

Eli Lilly and Co's quarterly other inventories increased from Sep. 2025 (CHF-31 Mil) to Dec. 2025 (CHF34 Mil) but then declined from Dec. 2025 (CHF34 Mil) to Mar. 2026 (CHF29 Mil).

Eli Lilly and Co's annual other inventories declined from Dec. 2023 (CHF89 Mil) to Dec. 2024 (CHF56 Mil) and declined from Dec. 2024 (CHF56 Mil) to Dec. 2025 (CHF34 Mil).

Eli Lilly and Co Inventories, Other Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Inventories, Other Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.50 8.29 88.56 56.17 34.27

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.89 -1.14 -30.57 34.27 29.13
XSWX:LLY
99GF Score
Eli Lilly and Co XSWX:LLY
Inventories, Other is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Frequently Asked Questions Learn more about Inventories, Other →
What does a Inventories, Other of CHF29 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Inventories, Other of CHF29 Mil as of Mar. 2026. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Inventories, Other too high?
Eli Lilly and Co's current Inventories, Other is CHF29 Mil. Overall, Eli Lilly and Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Inventories, Other compare to JNJ and ABBV?
Eli Lilly and Co's Inventories, Other of CHF29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Other for a Drug Manufacturers company?
A good Inventories, Other depends on the Drug Manufacturers industry context. However, Inventories, Other should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Other mean?
A high Inventories, Other can signal that a stock is expensive relative to its fundamentals. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Inventories, Other is CHF29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,136.02, compared to a current price of CHF955.00 — trading 15.9% below its estimated fair value. The current Inventories, Other is CHF29 Mil. Eli Lilly and Co's overall GF Score™ is 99/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Other calculated?
Inventories, Other is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Inventories, Other is CHF29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF955.00 is trading 15.9% below its estimated GF Value™ of CHF1,136.02. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Inventories, Other: CHF29 Mil
  • GF Value™: CHF1,136.02 vs. price of CHF955.00 (15.9% below fair value)
  • GF Score™: 99/100 with 5 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
99GF Score

Get the complete analysis for XSWX:LLY

Inventories, Other is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF955.00
Price
CHF1,136.02
GF Value